Berberine: a Potential Multipotent Natural Product to Combat Alzheimer's Disease

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2011 Aug 11

PMID 21829148

Citations 51

Authors

Hong-Fang Ji

Liang Shen

Affiliations

Soon will be listed here.

Abstract

With the accelerated aging of human society Alzheimer's disease (AD) has become one of the most threatening diseases in the elderly. However, there is no efficient therapeutic agent to combat AD. Berberine is a natural isoquinoline alkaloid that possesses a wide range of pharmacological effects. In the present paper, we review the multiple activities of berberine, including antioxidant, acetylcholinesterase and butyrylcholinesterase inhibitory, monoamine oxidase inhibitory, amyloid-b peptide level-reducing and cholesterol-lowering activities, which suggest that berberine may act as a promising multipotent agent to combat AD.

Citing Articles

Research progress on pharmacological effects and bioavailability of berberine.

Cui Y, Zhou Q, Jin M, Jiang S, Shang P, Dong X Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):8485-8514.

PMID: 38888754 DOI: 10.1007/s00210-024-03199-0.

Exploring the Therapeutic Potential of Alkaloids in Alzheimer's Disease Management.

Singh R, Rani N, Kaur R, Chahal G, Kumar P, Kaur G Cent Nerv Syst Agents Med Chem. 2024; 24(2):206-218.

PMID: 38213138 DOI: 10.2174/0118715249269092231109181638.

Astrocyte-Derived Extracellular Vesicles for Ischemic Stroke: Therapeutic Potential and Prospective.

Wang X, Li A, Fan H, Li Y, Yang N, Tang Y Aging Dis. 2023; 15(3):1227-1254.

PMID: 37728588 PMC: 11081164. DOI: 10.14336/AD.2023.0823-1.

Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease.

Vrabec R, Blunden G, Cahlikova L Int J Mol Sci. 2023; 24(5).

PMID: 36901826 PMC: 10003045. DOI: 10.3390/ijms24054399.

The potential for traditional Chinese therapy in treating sleep disorders caused by COVID-19 through the cholinergic anti-inflammatory pathway.

Xie X, Zhang N, Fu J, Wang Z, Ye Z, Liu Z Front Pharmacol. 2022; 13:1009527.

PMID: 36299906 PMC: 9589290. DOI: 10.3389/fphar.2022.1009527.

References

Ingkaninan K, Phengpa P, Yuenyongsawad S, Khorana N . Acetylcholinesterase inhibitors from Stephania venosa tuber. J Pharm Pharmacol. 2006; 58(5):695-700. DOI: 10.1211/jpp.58.5.0015. View

Markesbery W . Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997; 23(1):134-47. DOI: 10.1016/s0891-5849(96)00629-6. View

Chen J, Yan S . Role of mitochondrial amyloid-beta in Alzheimer's disease. J Alzheimers Dis. 2010; 20 Suppl 2:S569-78. DOI: 10.3233/JAD-2010-100357. View

Bhutada P, Mundhada Y, Bansod K, Tawari S, Patil S, Dixit P . Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res. 2011; 220(1):30-41. DOI: 10.1016/j.bbr.2011.01.022. View

Perry T, Greig N . The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis. 2003; 4(6):487-96. DOI: 10.3233/jad-2002-4605. View

Wang X, Wang R, Xing D, Su H, Ma C, Ding Y . Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci. 2005; 77(24):3058-67. DOI: 10.1016/j.lfs.2005.02.033. View

Hardy J, Allsop D . Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991; 12(10):383-8. DOI: 10.1016/0165-6147(91)90609-v. View

Yokozawa T, Satoh A, Cho E, Kashiwada Y, Ikeshiro Y . Protective role of Coptidis Rhizoma alkaloids against peroxynitrite-induced damage to renal tubular epithelial cells. J Pharm Pharmacol. 2005; 57(3):367-74. DOI: 10.1211/0022357055470. View

Riederer P, Lachenmayer L, Laux G . Clinical applications of MAO-inhibitors. Curr Med Chem. 2004; 11(15):2033-43. DOI: 10.2174/0929867043364775. View

10.

Brown D, Kozlowski H . Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases. Dalton Trans. 2004; (13):1907-17. DOI: 10.1039/b401985g. View

11.

Greig N, Utsuki T, Yu Q, Zhu X, Holloway H, Perry T . A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2002; 17(3):159-65. DOI: 10.1185/0300799039117057. View

12.

Kong L, Cheng C, Tan R . Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med. 2001; 67(1):74-6. DOI: 10.1055/s-2001-10874. View

13.

Huang L, Shi A, He F, Li X . Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010; 18(3):1244-51. DOI: 10.1016/j.bmc.2009.12.035. View

14.

Butterfield D, Reed T, Newman S, Sultana R . Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med. 2007; 43(5):658-77. PMC: 2031860. DOI: 10.1016/j.freeradbiomed.2007.05.037. View

15.

Imanshahidi M, Hosseinzadeh H . Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008; 22(8):999-1012. DOI: 10.1002/ptr.2399. View

16.

Wolozin B . Cholesterol and the biology of Alzheimer's disease. Neuron. 2004; 41(1):7-10. DOI: 10.1016/s0896-6273(03)00840-7. View

17.

Cummings J . Alzheimer's disease. N Engl J Med. 2004; 351(1):56-67. DOI: 10.1056/NEJMra040223. View

18.

Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido T . Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun. 2006; 352(2):498-502. DOI: 10.1016/j.bbrc.2006.11.043. View

19.

Yokozawa T, Ishida A, Kashiwada Y, Cho E, Kim H, Ikeshiro Y . Coptidis Rhizoma: protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components. J Pharm Pharmacol. 2004; 56(4):547-56. DOI: 10.1211/0022357023024. View

20.

Huang L, Luo Z, He F, Shi A, Qin F, Li X . Berberine derivatives, with substituted amino groups linked at the 9-position, as inhibitors of acetylcholinesterase/butyrylcholinesterase. Bioorg Med Chem Lett. 2010; 20(22):6649-52. DOI: 10.1016/j.bmcl.2010.09.013. View